Biotechnology
Healthcare
Technology

Advaxis

$1.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-9.55%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Advaxis and other stocks, options, ETFs, and crypto commission-free!

About ADXS

Advaxis, Inc. Common Stock, also called Advaxis, is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. Read More It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Employees
58
Headquarters
Princeton, New Jersey
Founded
1987
Market Cap
12.59M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
195.33K
High Today
$1.55
Low Today
$1.38
Open Price
$1.55
Volume
356.55K
52 Week High
$24.60
52 Week Low
$1.38

Collections

Biotechnology
Healthcare
Technology
Health
Cancer Prevention
Medical
Therapy
2013 IPO

ADXS Earnings

-$1.32
-$0.89
-$0.47
-$0.04
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Sep 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.